Alte(RNA)tives: Out-Licensing, In-Licensing, Co-Development

We are interested in collaborations with pharmaceutical and biotechnology companies that wish to develop new products based on our technology for cancer, infectious diseases and beyond. Our universal platform can transform a partner’s proprietary antigens into RNA-based vaccines.

Our oncological products, CV9103/4 and CV9201/2, have already demonstrated promising results in the clinical development phase. In 2014, we successfully out-licensed the therapeutic lung cancer vaccine CV9202 to Boehringer Ingelheim. We are continuing clinical development of CV9104 and seek a strong partner who will assist us in bringing it to market.

Our RNAdjuvant® is available for combination with protein or peptide vaccines. For this product we seek partners who have promising vaccine candidates and hope to improve their product through our RNA-based adjuvant.
Cooperation opportunities are diverse. Please feel free to contact us to discuss the possibilities for an optimal, customizable solution.

Your contact

Dr. Achim Loehr
Vice President Business Development
contact via e-mail

CureVac's Scientific Publications

can be found here...